Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib

Abstract Background Pancreatic adenocarcinoma (PC) is an aggressive malignancy with limited treatment options. The poor prognosis primarily stems from late-stage diagnosis and when the disease has become therapeutically challenging. There is an urgent need to identify specific biomarkers for cancer...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Weiyu Ge, Yanling Wang, Ming Quan, Tiebo Mao, Evelyne Y. Bischof, Haiyan Xu, Xiaofei Zhang, Shumin Li, Ming Yue, Jingyu Ma, Haiyan Yang, Lei Wang, Zhengyuan Yu, Liwei Wang, Jiujie Cui
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2024-03-01
سلاسل:	Molecular Cancer
الموضوعات:	Pancreatic adenocarcinoma ARNTL2 Prognosis Erlotinib Targeted therapy, precision oncology
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12943-024-01965-5
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!